CHEK2 Pathogenic Variants Associated With Breast and Other Cancers
A retrospective evaluation of lab results linked the likelihood of certain cancer types with the presence of specific pathogenic variants in CHEK2.
Related Articles
Metastatic Breast Cancer Cases Underreported, Patients Not Receiving Optimal Care
Experts have highlighted the need to improve data collection for metastatic breast cancer, end the stigma surrounding the disease, and improve patient outcomes via equitable…
¹⁷⁷Lu-PSMA-617 Improves Upon Enzalutamide in mCRPC
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Single Question Can Predict Treatment Discontinuation in MM Patients
A single question can be used to predict early treatment discontinuation in patients with multiple myeloma, a study suggests.
Alectinib Outperforms Chemo in ALK+ NSCLC
Adjuvant alectinib improved disease-free survival when compared to platinum-based chemotherapy in patients with ALK-positive non-small cell lung cancer in a phase 3 trial.
Olaparib Improves PFS, OS in BRCA-Like Ovarian Cancer
Adding olaparib to bevacizumab maintenance can improve outcomes in patients with BRCA-like, high-grade epithelial ovarian cancer, data suggest.
Gene Expression Score May Guide Treatment in Uveal Melanoma
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
MRI-Guided Neoadjuvant Chemo May Benefit Patients With HR-, HER2+ Breast Cancer
Early data suggest that using MRI to guide neoadjuvant chemotherapy may be beneficial for patients with stage II-III, HR-, HER2+ breast cancer.
Cancer Survivors Have Higher Risk of Functional Disability
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Corrections, Retractions Issued for Papers by Dana-Farber Researchers
Several corrections and retractions have been issued for study reports written by researchers at the Dana-Farber Cancer Institute since errors in these and other papers…
Trastuzumab Deruxtecan May Fulfill Unmet Need in HER2-Overexpressing NSCLC
Trastuzumab deruxtecan demonstrated activity in a phase 2 trial of patients with HER2-overexpressing, relapsed/refractory, unresectable and/or metastatic NSCLC.